Geninus Inc

Geninus Inc operates with a price-to-book ratio of 16.21 and a price-to-tangible-book ratio of 16.21, indicating a premium valuation relative to its equity base. The company's liquidity position is characterized by a current ratio of 0.77, suggesting potential short-term liquidity constraints. Despite holding KRW 6,619,223,220 in cash and equivalents, the company's long-term debt of KRW 9,131,465,210 offsets this liquidity, resulting in a net cash negative position. The company's profitability metrics are weak, with a return on equity of -1.9088 and a return on assets of -0.4415, both significantly below industry norms for biotechnology firms. Operating income of -KRW 11,671,177,570 and a net loss of -KRW 17,373,136,630 highlight the company's current unprofitability. Gross profit of KRW 173,018,800 is minimal relative to revenue of KRW 10,483,373,200, indicating low margin efficiency. Geographically, Geninus Inc's revenue is concentrated in South Korea, with no disclosed international segments. The company's services are primarily focused on bioinformatics analysis, genetic testing, and cancer genome solutions, with no material diversification across product lines. This concentration increases exposure to local market conditions and regulatory changes. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The operating cash flow of -KRW 7,079,975,050 and free cash flow of -KRW 15,511,289,300 indicate ongoing cash burn, which could constrain future growth initiatives. Capital expenditures of -KRW 1,379,187,670 suggest ongoing investment in infrastructure, but the negative cash flow limits the ability to sustain such investments. Risk factors include a medium liquidity risk due to the current ratio of 0.77 and a net cash negative position. The company's dilution risk is low, with no significant dilution sources identified in the latest filings. However, the negative operating and free cash flows increase the risk of future dilution if the company requires additional capital. Recent events include the continued focus on bioinformatics and genetic testing services, with no material changes in the company's strategic direction. The company's recent financial performance has been marked by significant losses, which may impact investor confidence and access to capital.